Cancer incidence and mortality were reviewed in patients (683) who, during the period 1969-1988, had been attending the Cardiological Center of Pisa University for more than 1 year for valvular (494), ischemic (183), or myocardial (6) disease.
Oral anticoagulant therapy (tromexan, acenocoumarol or warfarin) was administered to 312 of these 693 patients and regulated to prolong prothrombin time to a value between 20% and 40% of normal controls.
Cancer incidence and mortality in the 312 patients treated with anticoagulants were compared with that of the 381 patients who did not receive this therapy.
The total observation period was 1415 patient-years (555 for males and 860 for females) in the former and 1617 patient-years (735 males and 882 females) in the latter.
The proportion of the patient-years of the men over 45 was higher in the group treated with anticoagulants (83%) than in the controls (72%) (p<001).
The proportion of the patient-years of the women over 45 was also higher in the former (84% vs 62% ; p<001).
Six cancers were observed in the patients treated with oral anticoagulants (3 men, 3 women), while 12 cancers occurred in the control group (9 men, 3 women).
There were 3 deaths in the former (1 man, 2 women) and 6 in the latter (5 men, 1 woman).
On the basis of the national tumor registry rates, deaths expected in men and women on oral anticoagulants were 3 and 2.
Mots-clés Pascal : Acénocoumarol, Warfarine, Anticoagulant, Cardiopathie, Cardiopathie coronaire, Facteur risque, Tumeur maligne, Epidémiologie, Homme, Incidence, Mortalité, Coumarine dérivé, Appareil circulatoire pathologie
Mots-clés Pascal anglais : Warfarin, Anticoagulant, Heart disease, Coronary heart disease, Risk factor, Malignant tumor, Epidemiology, Human, Incidence, Mortality, Coumarine derivatives, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0118821
Code Inist : 002B04B. Création : 09/06/1995.